It was formally published in September 2019, replaced ISO 14117:2012, and was confirmed again in 2025.
Test Systems
GtestWorks Automated Testing Platform
VectWorks 3.0 Electrical Performance Test Software
This page provides a structured interpretation of ISO 14117:2019, EMC test protocols for active implantable medical devices, covering the standard background, development history, scope, frequency segmentation and test methods, core test items, clinical environment protection requirements, accompanying document obligations, and the relationship with domestically adopted standards.
If you are preparing standard adoption work, registration communication, or EMC test plans for implantable cardiac devices, start with the standard profile, frequency segmentation, and core test items. If your focus is hospital scenarios and documentation obligations, jump directly to the clinical protection and accompanying document sections.
ISO 14117:2019 is the core international EMC test protocol for active implantable cardiovascular medical devices. It focuses on the safety and functional stability of implantable cardiac pacemakers, implantable cardioverter defibrillators, and cardiac resynchronization devices under real electromagnetic environments. Compared with conventional EMC standards for external medical electrical equipment, it is much more concerned with whether an implanted device may be inhibited, falsely triggered, deliver inappropriate therapy, or suffer permanent parameter changes due to external electromagnetic fields.
It was formally published in September 2019, replaced ISO 14117:2012, and was confirmed again in 2025.
The protocol covers exposure sources from static magnetic fields and low-frequency fields to radiated fields from handheld wireless transmitters.
The target products are implantable cardiovascular devices that are life-sustaining or clinically critical.
The standard asks whether the device can still sense, pace, defibrillate, and resynchronize correctly under exposure conditions.
Broadcast services, EAS systems, RFID, maglev transportation, wireless charging, mobile phones, and two-way radios all contribute to a more complicated environment for implantable cardiac devices. The value of ISO 14117:2019 is that it turns those real-world scenarios into verifiable EMC test protocols.
Implantable devices involve long lead coupling, microvolt-level cardiac sensing, life-supporting functionality, and long-term in-body exposure. General EMC logic does not fully capture those risks, so the international standard system treats them with a dedicated methodology.
For companies developing and registering implantable pacemakers, ICDs, and CRT systems, ISO 14117:2019 is not merely a laboratory reference. It influences sample design, lead configuration, worst-case identification, IFU warnings, and international market access.
This section helps teams quickly confirm the international status of ISO 14117:2019, its committee structure, classification position, and how it fits into the ISO 14708 family.
| Item | Content |
|---|---|
| Standard Number | ISO 14117:2019 |
| Title | Active implantable medical devices — Electromagnetic compatibility — EMC test protocols for implantable cardiac pacemakers, implantable cardioverter defibrillators and cardiac resynchronization devices |
| Issuing Organization | International Organization for Standardization, ISO |
| Edition | Second edition, published in September 2019 |
| Length | 134 pages |
| Technical Committee | ISO/TC 150/SC 6 Active Implants |
| Scope Position | Core international EMC protocol for implantable cardiac devices |
Over the last two decades, patients with implantable cardiovascular devices have been exposed to a growing number of electromagnetic sources in daily life. Beyond broadcast and basic wireless communication, the exposure picture now includes EAS gates, RFID systems, maglev transportation, wireless charging, and a large number of handheld communication devices. For devices that may be life-sustaining, the consequences of EMC failure can be severe, which is why the protocol has had to evolve.
| Normative Reference | Role |
|---|---|
| ISO 14708-1:2014 | General requirements for active implantable medical devices, providing the basic safety and marking framework |
| ISO 14708-2:2019 | Particular requirements for implantable cardiac pacemakers |
| ISO 14708-6:2019 | Particular requirements for implantable cardioverter defibrillators |
| Relevant ICNIRP guidance | Theoretical support for high-frequency field exposure assessment |
Understanding ISO 14117:2019 requires looking not only at the final clauses, but also at how the protocol evolved from the 2012 edition and what real technical problems the second edition set out to solve.
The first edition established a systematic EMC test framework for implantable pacemakers and ICDs. It broke a complex in-body EMC problem into practical test items such as induced lead current, protection against continuous fault, protection against short-duration continuous-wave exposure, and a combination of injection and radiated test methods.
As wireless services expanded and multi-electrode lead technology advanced, the 2012 edition became less complete in areas such as the boundary frequency between injection and radiated testing, the scientific basis for bipolar test levels, treatment of low-frequency transient exposure, and naming of multi-port lead systems.
| 2019 Change Item | Details | Why It Matters |
|---|---|---|
| New terms | Added definitions such as interference mode and transient exposure | Makes test interpretation and pass/fail judgment clearer |
| Boundary frequency change | The division between injection and radiated testing moved from 450 MHz to 385 MHz | Improves coverage of newer wireless services |
| Clarification of Clause 4.4 | Refined requirements for short-duration exposure to continuous-wave sources | Improves execution consistency across labs |
| New Clause 4.10 | Introduced low-frequency transient exposure requirements from 16.6 Hz to 167 kHz | Responds to applications such as access gates and wireless charging |
| Recognition of multi-electrode leads | Brought IS-4 and DF-4 systems into the protocol | Adapts the standard to modern lead technology |
| New Clause 7.4 | Requires minimum separation distance disclosure for handheld transmitters | Strengthens practical clinical and patient-use guidance |
| New Annexes N and O | Handle multi-electrode connections and example transient exposure methods | Improves practical operability for more complex test setups |
The real shift in the 2019 edition is that the protocol moves beyond traditional stable environments into newer wireless environments, transient magnetic-field exposure, and multi-port lead systems. That makes it closer to both real-world exposure and the technical reality of current implantable devices.
This part defines where the standard applies and explains why injection testing, radiated testing, and unipolar versus bipolar test levels are selected differently.
| Applicable Device Type | Description |
|---|---|
| Implantable cardiac pacemaker | An implantable electronic device used to treat bradycardia |
| Implantable cardioverter defibrillator, ICD | A device used to detect and terminate life-threatening arrhythmias |
| CRT-P / CRT-D | Devices that provide cardiac resynchronization therapy in addition to pacing or defibrillation functions |
| Transvenous or epicardial lead systems | The protocol mainly addresses pulse generators used with conventional lead systems |
The second edition explicitly recognizes multi-electrode lead systems such as IS-4 and DF-4, and Annex N provides a generic naming and connection approach for multi-port, multi-electrode devices.
| Frequency Range | Main Test Method | Main Exposure Sources Considered |
|---|---|---|
| 0 Hz ≤ f < 385 MHz | Voltage injection testing | Power systems, low-frequency magnetic fields, EAS, RFID, mid-frequency fields, and some industrial or broadcast sources |
| 385 MHz ≤ f ≤ 3000 MHz | Radiated testing | Mobile phones, Wi-Fi, Bluetooth, radios, and other short-range wireless devices |
| Configuration | Coupling Characteristic | Main Test Logic |
|---|---|---|
| Unipolar | Larger loop area and stronger coupling | Usually evaluated at full test level as a worst-case condition |
| Bipolar | Shorter tip-to-ring distance and lower differential induced voltage | Differential-mode test levels are typically set at 10% of the unipolar amplitude |
| Multi-port multi-electrode | Needs evaluation of different electrode-pair combinations | Connections are defined according to Annex N naming and setup logic |
The value of ISO 14117:2019 lies in how it breaks EMC risk for implantable devices into dedicated test items with clear frequency ranges, purposes, and failure modes, rather than relying on a single broad immunity-field requirement.
| Clause | Test Item | Frequency Range | Test Type |
|---|---|---|---|
| 4.2 | Induced current in electrode leads | 16.6 Hz-500 kHz | Injection test |
| 4.3 | Protection against continuous fault from ambient electromagnetic fields | 0 Hz-10 MHz | Injection test |
| 4.4 | Protection against fault from temporary exposure to continuous-wave sources | Specified bands | Injection test |
| 4.5 | Protection against sensing EMI as cardiac signals | Specified bands | Injection test |
| 4.6 / 4.7 | Static magnetic field protection | 0 Hz | Magnetic field test |
| 4.8 | AC magnetic field exposure protection | 1 kHz-140 kHz | Magnetic field test |
| 4.9 | Radiated high-frequency field protection | 385 MHz-3000 MHz | Radiated test |
| 4.10 | Low-frequency transient exposure protection | 16.6 Hz-167 kHz | Injection test |
This test examines whether low-frequency magnetic fields induce voltages and currents in the leads that could increase local tissue current density and create thermal or stimulation-related risk. Tissue-equivalent interface circuits and low-pass filters are commonly used to model the in-body environment.
Clause 4.3 focuses on whether the device develops persistent functional abnormalities under sustained exposure, while Clause 4.4 focuses on whether short-duration continuous-wave exposure pushes the device into an unintended operating state and whether it recovers properly afterward.
| Test Item | Main Concern | Typical Risk |
|---|---|---|
| EMI sensed as cardiac signals | Whether the device mistakes external interference for P-waves or R-waves | Pacing inhibition, inappropriate tracking, false ICD therapy |
| Static magnetic field protection | Behavior under 1 mT and 50 mT static magnetic fields | Mode switching, false magnetic response, parameter abnormality |
| AC magnetic field exposure | Influence of low-frequency magnetic sources such as RFID, EAS, and inductive equipment | Temporary malfunction and abnormal lead coupling |
| Radiated high-frequency fields | Exposure to handheld wireless devices and communication systems | Sensing abnormality, incorrect therapy, or loss of function |
| Transient exposure test | Transient and permanent fault behavior after short pass-by magnetic exposure | Short-duration misbehavior and failure to recover after exposure |
Clause 6 focuses on two of the most severe high-energy exposure scenarios in clinical practice: high-frequency electrosurgery and external defibrillation. For implantable devices, these scenarios are much more likely than routine wireless environments to cause direct damage or critical functional abnormality.
| Test Item | Exposure Source | Verification Target |
|---|---|---|
| High-frequency electrosurgery protection | Electrosurgical and RF treatment equipment | Verify that the device is not damaged and that normal function is recovered |
| External defibrillation protection | External defibrillation pulse | Verify that function, parameters, and stored data do not undergo unacceptable change |
EMC risk in clinical settings is not usually a stable and easily predictable continuous field. It often involves high-energy pulses, complicated coupling paths, and patient-related variation. The significance of Clause 6 is that it simulates those high-risk conditions before market entry rather than after an incident occurs.
ISO 14117:2019 does not stop at laboratory verification. It also requires the manufacturer to provide sufficient EMC risk information in accompanying documents so clinicians and patients can understand the practical limits of use.
| Clause | Required Content | Why It Matters |
|---|---|---|
| 7.1 | Disclose permanent programmable sensitivity settings that do not satisfy Clause 4.4 | Avoid hiding EMC vulnerability under higher-risk programmed conditions |
| 7.2 | Describe cardioversion-related modes | Helps clinicians understand device behavior under specific interference conditions |
| 7.3 | Disclose known potentially hazardous behaviors | Warns users away from higher-risk scenarios |
| 7.4 | Provide minimum separation distances from handheld transmitters | Turns the EMC conclusion into practical guidance for clinicians and patients |
EMC risk for implantable devices cannot be managed by laboratory control alone. Many of the important risks come from actual patient exposure in daily life. That is why the manufacturer has to translate laboratory findings into understandable warnings and minimum separation recommendations.
The second edition makes minimum separation distance disclosure explicit, which means the standard no longer stops at a simple pass-or-fail outcome. It requires the manufacturer to convert EMC conclusions into clear operational boundaries for real use scenarios, especially around phones, radios, and other handheld transmitters.
The device types, frequency bands, power levels, and separation conditions that create risk should be stated clearly.
Test conclusions should become clear and usable warnings rather than remaining as laboratory terms only.
Sensitivity, sensing configuration, and therapy mode can all change EMC behavior and therefore need to be addressed together.
For implantable devices, accompanying documents are not an optional extra. They are part of the EMC risk-control strategy itself.
ISO 14117:2019 is not only an international standard. It has already entered the domestic adoption path and now connects directly with the active implantable medical device standard system used in China.
| Related Standard or Work | Relationship |
|---|---|
| YY/T 1874-2023 / ISO 14117:2019 | The NMPA has completed an identical adoption, keeping the domestic text aligned with the international standard |
| ISO 14708-1:2014 | Base general-safety standard for active implantable medical devices |
| ISO 14708-2:2019 | Particular requirements for cardiac pacemakers |
| ISO 14708-6:2019 | Particular requirements for implantable defibrillators |
The value of ISO 14117:2019 is not that it simply adds more EMC tests. It establishes a complete methodology and documentation framework for implantable cardiovascular devices, centered on real electromagnetic exposure, critical therapy functions, and patient-use safety.
